Your browser doesn't support javascript.
loading
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza, Mansoor R; Benigno, B; Dørum, A; Mahner, S; Bessette, P; Barceló, I Bover; Berton-Rigaud, D; Ledermann, J A; Rimel, B J; Herrstedt, J; Lau, S; du Bois, A; Herráez, A Casado; Kalbacher, E; Buscema, J; Lorusso, D; Vergote, I; Levy, T; Wang, P; de Jong, F A; Gupta, D; Matulonis, U A.
Afiliación
  • Mirza MR; Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: mansoor@rh.regionh.dk.
  • Benigno B; Northside Hospital, Atlanta, GA, USA.
  • Dørum A; Radiumhospitalet, Oslo University Hospital, NSGO, Oslo, Norway.
  • Mahner S; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, AGO, Munich, Germany.
  • Bessette P; Sherbrooke University, Sherbrooke, QC, Canada.
  • Barceló IB; Hospital Son Llàtzer, GEICO, Palma de Mallorca, Spain.
  • Berton-Rigaud D; Institut de Cancérologie de l'Ouest Centre René Gauducheau, GINECO, Saint-Herblain, France.
  • Ledermann JA; UCL Cancer Institute, University College London, NCRI, London, UK.
  • Rimel BJ; Cedars-Sinai Medical Center, West Hollywood, CA, USA.
  • Herrstedt J; Odense University Hospital, Odense, Denmark; Zealand University Hospital, NSGO, Roskilde, Denmark.
  • Lau S; McGill University, Montreal, QC, Canada.
  • du Bois A; Kliniken Essen Mitte, AGO, Essen, Germany.
  • Herráez AC; Hospital Clínico San Carlos, GEICO, Madrid, Spain.
  • Kalbacher E; Centre Hospitalier Régional et Universitaire de Besançon, GINECO, Besançon, France.
  • Buscema J; Arizona Oncology Associates, Tucson, AZ, USA.
  • Lorusso D; Fondazione Policlinico Universitario a Gemelli IRCCS, Istituto Nazionale dei Tumori, MITO, Milan, Italy.
  • Vergote I; University of Leuven, Leuven Cancer Institute, BGOG, Leuven, Belgium.
  • Levy T; Wolfson Medical Center, ISGO, Holon, Israel.
  • Wang P; GlaxoSmithKline, Waltham, MA, USA.
  • de Jong FA; GlaxoSmithKline, Zug, Switzerland.
  • Gupta D; GlaxoSmithKline, Waltham, MA, USA.
  • Matulonis UA; Dana-Farber Cancer Institute, Boston, MA, USA.
Gynecol Oncol ; 159(2): 442-448, 2020 11.
Article en En | MEDLINE | ID: mdl-32981695
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Piperidinas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Carcinoma Epitelial de Ovario / Indazoles / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Piperidinas / Inhibidores de Poli(ADP-Ribosa) Polimerasas / Carcinoma Epitelial de Ovario / Indazoles / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Female / Humans / Middle aged Idioma: En Año: 2020 Tipo del documento: Article